

Optimal prevention strategies for chronic diseases in a compartmental disease trajectory model

Katharina Ledebur^{1,3,4}

Alexandra Kautzky-Willer²

Stefan Thurner^{1,3,5}

Peter Klimek^{1,3,4*}

¹Institute of the Science of Complex Systems, CeDAS, Medical University of Vienna, Spitalgasse 23, A-1090 Vienna, Austria

²Gender Medicine Unit, Division of Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna, Spitalgasse 23, A-1090 Vienna, Austria

³Complexity Science Hub Vienna, Josefstädter Strasse 39, A-1080 Vienna, Austria

⁴Supply Chain Intelligence Institute Austria, Josefstädter Strasse 39, A-1080 Vienna, Austria

⁵Santa Fe Institute, 1399 Hyde Park Road, Santa Fe, NM 87501, USA

*peter.klimek@meduniwien.ac.at

Abstract

In countries with growing elderly populations, multimorbidity poses a significant healthcare challenge. Despite its pressing development, important questions remain on how to model the development of multimorbidity. Leveraging a comprehensive dataset from approximately 45 million hospital stays spanning 17 years in Austria, we propose a compartmental model, traditionally used in infectious diseases, describing chronic disease trajectories across 132 distinct multimorbidity patterns (compartments). Our compartmental disease trajectory model (CDTM) forecasts changes in the incidence of 131 diagnostic groups and their combinations until 2030, highlighting patterns involving hypertensive diseases with cardiovascular diseases and metabolic disorders. We additionally use the model to pinpoint specific diagnoses with the greatest potential for preventive interventions to promote healthy aging. According to our model, a 5% reduction in new cases of hypertensive disease (I10–I15) leads to a 0.57 (0.06)% reduction in all-cause mortality over a 15-year period, and a 0.57 (0.07)% reduction in mortality for malignant neoplasms (C00–C97). Furthermore, we use the model to assess the long-term consequences of the Covid-19 pandemic on hospitalizations, revealing earlier and more frequent hospitalizations across multiple diagnoses. Our fully data-driven approach identifies leverage points for proactive preparation by physicians and policymakers to reduce the overall disease burden in the population, emphasizing a shift toward patient-centered care.

1 Introduction

In many western countries, there is a persistent trend of increasing life expectancy [1]. From 1999 to 2019, life expectancy in Europe increased by 5.8 years [2], and specifically, in Austria by 3.1 and 4.5 years for women and men, respectively [3]. By 2050, the proportion of the Austrian population over 65 years will increase from 19.4% (2019) to 27.7% [4, 5]. However, since 2011, the rate of increase in life expectancy has been slowing down in several EU countries, mainly due to a slowdown in improvements in mortality from cardiovascular disease and potentially due to increasing prevalence of diabetes and obesity [6]. In Austria, the life expectancy in self-perceived (very) good health decreased from 65.9 (2014) to 63.1 years (2019) for men and from 66.6 (2014) to 64.7 years (2019) for women [7, 8]. The increase in total life expectancy together with the decrease of life expectancy under healthy conditions may be explained in part by excellent acute medical care and emergency medicine, and at the same time, a lack of adequate prevention programs for noncommunicable diseases (NCDs) which would be necessary to improve health of an aging population [9].

An aging population is associated with an increase in the prevalence of chronic diseases [10]. As chronic diseases often share risk factors, this is expected to increase the number of people with multiple health conditions [11]. This phenomenon, referred to as "multimorbidity", is one of the major challenges facing countries with aging populations [12]. Most research on the increase in multimorbidity focuses either on a small or a specific subset of individuals [13, 14, 15] and/or specific chronic diseases [16, 17, 18]. Research on multimorbidity itself, in a broader context is rare, despite its pressing development, and varies in terms of study setting, data sources, study population and type of measure [19]. One reason for this knowledge gap is the lack of a clear definition of multimorbidity [20]. Studies often define multimorbidity as the presence of a certain number of diagnoses (two or more). However, disease progression and treatment depend strongly on which diseases co-occur [21, 12]. An alternative to simply defining multimorbidity by the count of diagnoses would be to define multimorbidity as the presence of disease patterns in the form of sequences of diseases, individuals are diagnosed with over their life-course, so-called disease trajectories [22].

The field of network medicine has advanced the understanding of the nature of disease trajectories through numerous studies of so-called phenotypic comorbidity networks, where nodes represent diseases and links describe their associations, the observed relationships between diseases and various factors such as genetics, lifestyle, or environmental exposures. Population-wide electronic health records (EHR) or medical claims data have also allowed us to identify such trajectories on a large scale [21, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33]. Specifically, it was found that patients tend to develop diseases that are in close network proximity to diseases they have already been diagnosed with. This facilitates predicting future diseases based on medical history [23, 21].

A major challenge in studying long-term disease trajectories is the large number of possible disease combinations and their temporal permutations. By clustering frequently co-occurring diseases and quantifying how they condition each other, it is possible to reliably uncover long-term disease trajectories, as a series of disease combinations (health states), for populations within countries [22, 34]. However, studies on the temporal evolution of multimorbidity, especially in the context of an aging population, remain scarce, both in terms of retrospective data analyses [35, 36, 37], and for predictive modelling. The bottlenecks are methodological challenges and data requirements [38, 39].

There is a tradition of using both quantitative network-based approaches and compartmental frameworks, to describe the health status of individuals, to study the public health effects of interventions, and to forecast epidemiological developments in the context of infectious diseases. This became apparent during the Covid-19 pandemic, where such models played a pivotal role in decision support. While hitherto such modelling approaches have remained largely unexplored for NCDs. Why there is such a remarkable methodological gap between communicable and noncommunicable diseases is not entirely clear. One reason may be that it is not clear to date if and how the disease-causing mechanisms that underlie chronic diseases can be put into mathematical language.

Here, we close this gap by developing a compartmental model, based on a multimorbidity network, for the investigation of multimorbidity on the basis of chronic disease trajectory dynamics within the Austrian population. While for infectious disease dynamics compartments typically correspond to e.g. susceptible, infected, or recovered individuals, for chronic diseases these compartments correspond to different multimorbidity clusters and every patient is assigned a health state, a cluster, per year.

The approach is outlined in Figure 1. Using an extensive dataset covering all hospital diagnoses in Austria between 1997 and 2014 (approx. 45,000,000 hospital stays of about 9,000,000 individuals), a transition network between multimorbidity clusters describing patterns of co-occurring diseases (ICD-10 codes covered range from A00 to N99) was developed by Haug *et al.* (2020) [22]. Here, we extend this framework to a population-dynamics compartmental model and simulate the multimorbidity patterns of the entire Austrian population from 2003 to 2030, incorporating demographic changes (migration, birth, and death provided by the Austrian National Statistics Office) as well as individuals acquiring new diagnoses on the basis of their multimorbidity cluster, enabling both in- and out-of-sample predictions. Both, the incidences of the different diagnoses and the temporal development of multimorbidity within the population can be addressed in the new framework.

We demonstrate the versatility of this novel compartmental disease trajectory model (CDTM) in several case studies. Initially, we forward project the annual incidence of diagnoses (A00–N99) and combinations thereof in a baseline scenario. This projection considers the predicted changes in demographics by the national statistics office but no improvements in death rates, diagnostic procedures, treatments, etc. Subsequently, we conduct a series of simulations to assess the overall and long-term impact of hypothetical disease prevention efforts. We focus on specific diseases and assume that new therapies or increased surveillance lead to improved prevention rates for these




Figure 1. Workflow and the compartmental disease trajectory model (CDTM) presented in this article. (a) The diagnostic history of all patients (alive between 1/1/1997 and 12/31/2002) is collected. According to these diagnoses, each patient is assigned to a multimorbidity cluster as identified by Haug *et al.* (2020) [22]. The model is initialized in a state that is calibrated to the Austrian population at the beginning of 2003. We validate the model until 2014 and simulate the disease trajectories of the Austrian population until 2030. (b) The CDTM models the health states of the Austrian population by incorporating annual processes of birth, migration, and death and 132 compartments describing disease cluster. All individuals are assigned a disease cluster (compartment) each year based on their previous year’s cluster j (compartment) and the corresponding age (a)- and sex (g)-stratified transition probabilities ($q'_{g,a,k,j}$) (different layers). We model and calibrate a baseline scenario to simulate annual incidences of 131 diagnose groups and occurrences of 132 multimorbidity patterns (disease cluster). In addition we assess the impact of mitigation scenarios such as improvements in diagnoses or prevention efforts and Covid Shock scenarios on the overall health state of the Austrian population.

diagnoses, resulting in a reduction in new onset diagnoses. Our model enables us to compute how this decrease in diagnoses affects the risk to progress to other multimorbidity patterns and their associated mortality across the entire diagnostic spectrum. By comparing the simulations of each hypothetically prevented diagnosis, we can quantitatively estimate which kind of preventions lead to the greatest overall reduction in mortality. Additionally, we study scenarios for the long-term impact of the Covid-19 pandemic. We estimate the impact of sequelae of a SARS-CoV-2 infection on the disease burden and expected deaths in the Austrian population in a pessimistic and optimistic scenario.

2 Methods

2.1 Data Characteristics and Compartmental Disease Trajectory Model (CDTM)

The CDTM relies on a comprehensive dataset provided by the Austrian Ministry of Health. The dataset covers all hospital records from all hospitals in Austria from 1997 to 2014. It includes over 45 million stays for over 9 million different individuals. For each stay, the sex, age-group (5-year interval), duration of the stay, exit reason as well as main and side diagnoses on three digit level ICD-10 codes are recorded.

Using this dataset, Haug *et al.* [22] identified 132 multimorbidity patterns. These patterns, multimorbidity clusters, serve as nodes in a multiplex network, with directed edges representing transition probabilities between these patterns (see Supplementary Information for more details on the network construction). Each layer of the network corresponds to a specific 5-year age and sex group. The directed edges between two clusters k and j are weighted based on the age- (a) and sex (g) dependent probabilities ($q_{g,a,k,j}$) of transitioning from one cluster to another within a single time step.

These multimorbidity clusters provide the basis for the compartments describing health states in the CDTM (Figure 1b) and the corresponding transition probabilities are the basis of the rates between these compartments. We model the Austrian population by extracting all diagnoses (ranging from A00-N99) of individuals with a hospital stay in the dataset from 1997-2003 and assigning them a multimorbidity cluster (compartment or network

node) following Haug *et al.* (2020) [22]. We compare the extracted number of individuals per age and sex group with the actual population size according to Statistics Austria at the start of 2003 and add the difference into a compartment of individuals with no hospital stays at all (cluster 0) as the healthy population. (Figure 1a) [4]. Individuals in the population are modeled as random walkers transitioning over the multimorbidity clusters. In particular, the model assumes that an individual with sex, g , and age, a , assigned to cluster, k , transitions to another cluster j with probability $q_{g,a,k,j}$.

Each multimorbidity cluster is defined by a set of 131 probabilities $p_{c,d}$ describing the probability of being diagnosed with diagnose group d , given that the patient is in cluster c . We calculate for each cluster and diagnose group a probability of being diagnosed with the respective group when transitioning to that cluster based on the cluster memberships of the modelled Austrian population in 2003.

2.2 Calibration and Simulation

In each simulation year, individuals are assigned a specific multimorbidity cluster based on age and sex-dependent transition probabilities $q_{g,a,k,j}$. If an individual's cluster assignment differs from that of the previous simulation year, they are subsequently diagnosed with diseases in accordance with the probabilities associated with the 131 diagnostic groups corresponding to their new cluster ($p_{c,d}$). This dynamic process enables the model to project and predict disease incidences on a yearly basis.

Also on an annual basis the model incorporates several demographic factors: individuals are born, migrate, and pass away according to historical data and a baseline scenario of population movements provided by Statistics Austria [4]. The number of deaths per cause (i.e. a specific disease) are available until 2019. From 2019 onwards, our assumption is the distribution of deaths by cause, sex, and age from 2019.

To calibrate the model, we adjust the age and sex-dependent transition probabilities by applying an age-dependent factor. We reduce the transition probabilities for the first three ten-year age groups (0-29 years) by 65%, for the age group 30-39 years by 60%, for the age group 40-49 years by 40%, for the age group 50-59 years by 20% and for the age group 60-69 years by 10%. The transition probabilities of the last three ten-year age groups (70+ years) are not reduced. The reduction factors were estimated via a grid search comparing the number diagnoses per individual in the simulation of the model and the dataset. See Figure S2 a-d for the number of diagnoses per individual across 10-year age groups (0-9, 10-19,...) from the dataset and the model result for 2004-2006 and 2012-2014.

We simulate the model for the calibration period spanning from 2003 to 2014. During this calibration phase, the model computes, for each diagnosis group, age group, and sex group, the discrepancies in the diagnosed cases between the simulation result and data in age group a , referred to as $\delta d(a)$. The first three ten-year age groups are combined into one age group (0-29 years), the age groups 30-39 and 40-49 years are combined into one. The other age groups remain 10-year age groups. This simplification is introduced because the discrepancies among younger individuals grouped in ten-year age groups, are too small in the case of specific diagnosis groups. The $\delta d(a)$ values are subsequently distributed annually, factoring in age and sex groups, allowing for a refinement of the model and a more accurate representation of disease dynamics. See Figure S1 for incidences in 2014 from the dataset compared to the model result at the end of the calibration period, in 2014.

To distribute the discrepancies in diagnosed cases ($\delta d(a)$) across diagnostic groups, age groups, and sex groups, from 2015 onwards, we employ a rate calculation. Specifically, we determine a rate for each combination of diagnosis, age-, and sex group. We use the geometric mean of the rates from the data of the final three years of the calibration period, namely 2012, 2013, and 2014, for the forecast simulation period, spanning from 2015 to 2030.

2.3 Observables

We introduce several measures to describe the dynamics of the disease trajectories. The *relative incidence change* (ΔI_{rel}) of single diagnose groups refers to the measure of how the incidence of a particular diagnosis has changed in year $y + \Delta t$, relative to the initial incidence in year y .

$$\Delta I_{rel} = \frac{I_{y+\Delta t} - I_y}{I_y} \quad (1)$$

To study the development of multimorbidity in terms of the number of diagnoses received, we define *multimorbidity incidence* as the frequency of individuals receiving n diagnoses ($n = 1-3, 4-6, 7-9, >10$). To study the development of multimorbidity as specific disease patterns, we look at the *relative occurrence* of a multimorbidity cluster, c , per year y , which is defined as the ratio of transitions to cluster, c , to the total number of transitions in that year.

The decrease in all-cause mortality (total number of deaths) due to reduction of new-onset diagnoses is measured in *reduction in death numbers* and *prevented deaths per prevented diagnosis*. We measure the *reduction in death numbers* by comparing the total number of deaths in a simulation run where the new-onset diagnoses of a particular diagnose group is reduced by a factor, γ , to deaths due to all death causes in a simulation with no reduction. *Prevented deaths per prevented diagnoses* are computed by dividing the total number of deaths by the total number of reduced diagnoses for the simulation where a certain diagnose group is reduced by a factor γ .

The impact of the Covid-19 Shock on the overall disease burden is estimated by computing the difference in number of diagnoses from 2022-2030 between the main and the respective Covid-19 Shock scenario, compared to the main scenario (*difference in incidence*). Additionally, we compute the *average years until diagnosis* and compare the Covid-19 Shock to the main scenario. This quantifies how much earlier, on average, individuals are diagnosed with a diagnose group as a result of the simulated Covid-19 Shock.

2.4 Scenarios

Next to the baseline scenario we showcase scenarios demonstrating the versatility of the developed CDTM. We simulate scenarios for studying how reductions as well as increases in diagnoses affect the health state of the population.

To assess the potential impact of interventions such as prevention efforts or the introduction of new medications, we perform scenario simulations with modified transition probabilities. In this framework, we annually reduce the incidence of one of the 131 diagnostic groups, thereby allowing us to evaluate the cumulative effects of these interventions over time. To reduce the incidence of one diagnose, d , we reduce the transition probability $q_{g,a,k,j}$, by multiplying it by a factor γ (in our case $\gamma = 0.95$):

$$q'_{g,a,k,j} = (1 - p_{j,d})q_{g,a,k,j} + p_{j,d}p_{k,d}q_{g,a,k,j} + (1 - p_{k,d})p_{j,d}q_{g,a,k,j}\gamma \quad , \quad (2)$$

The first term in equation (2), refers to the transition probability of individuals who will not be diagnosed with d after transitioning from cluster k to j , the second term refers to the transition probability of individuals already diagnosed with d and the last term refers to the transition probability (reduced by a factor γ) of individuals who would be diagnosed with d after transitioning to cluster j .

We estimate how the Covid-19 pandemic might affect the future incidence of diagnoses and death numbers by implementing a "Covid-19 Shock". In the Covid-19 Shock scenario, we assume that every person in Austria has been infected with SARS-CoV-2 at least once by the year 2022. Subsequently, we simulate the associated mortality resulting from post-acute sequelae of SARS-CoV-2 infections based on empirical data [40]. To estimate the heightened likelihood of individuals being diagnosed with specific diseases following a SARS-CoV-2 infection, we employ Hazard Ratios (HR) reported in the retrospective cohort studies (Table S2). To calculate this increased probability, we analyze the frequency of diagnostic codes (per age- and sex group) specified in the retrospective cohort studies within the 131 diagnostic groups in the original dataset. Per age- and sex group, this frequency is then multiplied by the probability assigned to each diagnostic group. The resulting numbers are used to externally allocate the additional diagnoses within the population. Subsequently, we assign new multimorbidity clusters to individuals, taking into account all the diagnostic groups with which they have been diagnosed. For the annual number of deaths, we take derived death rates from the main scenario and multiply them by the number of diagnoses in the Covid-19 Shock scenarios.

3 Results

3.1 Impact of aging population on disease burden

The out-of-sample simulation time span ranges from 2015 to 2030. Within this period we evaluate predictions for annual changes in the incidence of the 131 diagnostic groups, thereby facilitating an exploration of the evolving disease burden within the population. Figure 2a illustrates the relative change in incidence (ΔI_{rel}) between 2030 and 2015 for selected diagnoses ($\Delta I_{rel} > 13\%$) and Figure 2b the absolute incidence values for the years 2015 (unfilled bars) and 2030 (filled bars). Increases in incidence are observed for diseases affecting the nervous system, the genitourinary system and the circulatory system. For other degenerative diseases of the nervous system (G30-G32) we observe $\Delta I_{rel} = 32.04\%$ (9.92), from 9,700 (9600) diagnoses in 2015 to 13,000 (1,300) in 2030. For malnutrition (E40-E46) we find an increase of 24.49% (9.92), from 2,200 (13) diagnoses in 2015 to 2,800 (17) in 2030. For renal failure (N17-N19), $\Delta I_{rel} = 29.21\%$ (1.63), increasing from 36,000 (590) diagnoses in 2015 to 46,800 (760) diagnoses in 2030. These are all diagnosis codes primarily prevalent in elderly patients. Whereas a decrease in ΔI_{rel} by 18.50% (5.00), from 15,800 (800) diagnoses in 2015 to 12,800 (640) in 2030, is visible for diseases affecting younger individuals such as behavioral disorders and diseases of the appendix (for information on incidence stratified by age, see Figure S3).

For age-standardized incidence values, the age structure in 2030 is standardized to the structure in 2015 (Figure 2c). An increase in age-standardized incidence, such as for renal failure (N17-N19), from 2,900 (50) diagnoses in 2015 to 3250 (50) in 2030, highlights that the changes in incidence observed in the Figure 2a and b are not influenced by demographic shifts (aging population) but by shifts in the overall health status of the population.

The CDTM further allows us to examine the development of the frequency of combinations of diagnoses from each multimorbidity cluster. We find that for 2030 compared to 2015 we find an increase in transition from disease cluster describing multimorbidity patterns with three inclusion diagnoses to cluster describing patterns with four inclusion diagnoses by 2.7%.

Figure 3a offers insight into the 20 most assigned multimorbidity cluster in 2015, comparing the relative occurrence of these combinations in both 2015 and 2030. We show the inclusion diagnoses per multimorbidity cluster. The most common multimorbidity clusters are primarily those including hypertensive diseases. This does not change during the forecast period. For the disease pattern describing the co-occurrence of hypertensive diseases (I10-I15), other forms of heart disease (I30-I52), diseases of arteries, arterioles and capillaries (I70-I79) and renal failure (N17-N19) we find an increase in relative occurrence from 1.73% to 3.0% from 2015 to 2030. The relative occurrence of the pattern including hypertension, other forms of heart disease, organic, including symptomatic, mental disorders (F00-F09) and renal failure, increases from 1.13% to 2.14%. The third highest increase in relative occurrence from 2.40% to 3.32% is observed for hypertensive diseases, other forms of heart disease and renal failure. Figure 3b contrasts the difference in this relative occurrence between 2030 and 2015, stratified by gender. The difference in relative occurrence between 2015 and 2030 varies for males and females mainly in disease patterns including renal failure. For instance, males show an increase of 1.70% and females an increase of 0.88% between 2015 and 2030 in the disease pattern encompassing hypertensive diseases, other forms of heart disease, diseases of arteries, arterioles, and capillaries, and renal failure.

3.2 Leverage points for optimal prevention schemes

Specific interventions can be expected to lead to decreases in incidence. In the following, for each diagnosis, we evaluate how much a relative reduction of 5% in the transition probabilities leading to new onsets of the diagnosis impacts all-cause mortality, see Figure 4. We show the 10 diagnoses with the largest effect on all-cause mortality only for potentially preventable diseases (by medication, prevention efforts, vaccinations, etc.) (Figure 4 a). These groups include C00-D49, E00-E99, F00-F99, I00-I99, J00-J99 and N00-N99. We find the greatest reduction in deaths per diagnosis for diseases affecting the circulatory system, neoplasms, endocrine, nutritional and metabolic diseases, and diseases of the respiratory system. Each bar refers to the average relative reduction in the number of deaths over a period of 15 years per reduced diagnoses over 10 iterations due to a 5% reduction in the transition probabilities of individuals who would be diagnosed with the corresponding diagnosis on the y-axis.

For hypertensive diseases (I10-I15) we find a reduction of 0.57 (0.06)%, for malignant neoplasms a reduction of 0.57 (0.07)% and for ischaemic heart diseases (I20-I25) a reduction of 0.53 (0.04)% in all-cause mortality. These diagnosis groups are the main causes of death in Austria [41]. Less important causes of deaths are diseases of veins




Figure 2. Relative change in annual incidence of diagnose groups with a relative absolute increase $> 13\%$ 2030 compared to 2015 relative to 2015 (a). Absolute values of annual incidence for 2030 and 2015 (b). Increases in annual incidence is primarily observed for fiseases affecting the nervous system, the genitourinary system and the circulatory system as well as malnutrition. Age standardized incidence in 2015 and 2030 (c). We assume the same population structure in 2030 as in 2015. This shows, that for some diagnose groups (i.e renal failure (N17-N19)) the model shows the change in incidence not only due to a change in the population structure but also due to a change in the health state of the population. In all panels, error bars indicate the mean relative error from 2010 to 2014. We only show diagnosis groups where we define a constant error (i.e. diagnose rates do not change over time). We exclude all diagnosis groups where the absolute error in 2014 is greater than 5% of the incidence in 2014 and greater than 500 cases per year, and all diagnosis groups where the error changes by 1.3 between 2010 and 2014.




Figure 3. Relative occurrence of the the 20 most common multimorbidity clusters in 2015. Relative occurrence in the simulation year 2015 and 2030 (a). We show the inclusion criteria of all 20 multimorbidity clusters. Especially clusters describing disease patterns containing hypertensive diseases (I10-I15) exhibit an increase between 2015 and 2030. Difference in relative occurrence 2030 compared to 2015 for females and males, respectively (b). Difference in occurrence between male and females is only visible for multimorbidity cluster including diseases of the genitourinary system.

(I80-I89) (0.36 (0.06)%) and disorders of the thyroid gland (E00-E07) (0.29 (0.05)%), suggesting that a reduction of new onsets of diseases in these diagnose groups leads to a reduction in potentially fatal sequelae.

To account for a potential bias due to differences in the incidence of the reduced diagnose group and potential sequelae, we compute the ratio of prevented deaths per prevented diagnose. Note that we do not just count the prevented diagnoses of the diagnosis group on the y-axis, but include all groups to account for the number of sequelae prevented. We find that there are 0.05 (0.01) prevented deaths per prevented diagnosis due to a reduction of 5% of new onset malignant neoplasms, suggesting improvements in prevention of malignant neoplasms as the optimal leverage point (Figure 4 b).

3.3 Impact of post-acute Covid-19 sequelae on population health

As another example, we evaluate the impact of the Covid-19 pandemic on the incidence rates of potential sequelae arising from SARS-CoV-2 infections, along with consequential shifts in all-cause mortality. In the pessimistic scenario 1, we reduce the HRs by 15%, and in scenario 2 by 40%. This reflects the potential influence of less severe viral variants and future vaccination campaigns. We analyze the difference in the total number of diagnoses accumulated over nine years (all new onset diagnoses from 2022-2030) between the baseline and Covid-19 Shock scenarios, compared to the baseline scenario (Figure 5a), as well as the average time until diagnosis between the main and the Covid-19 Shock scenarios (Figure 5b), serving as an indicator of expedited diagnosis within the Covid-19 Shock scenarios.

The largest differences between the baseline and Covid-19 Shock scenarios are observed for sequelae affecting the respiratory system, digestive system, and mental, behavioral, and neurodevelopment disorders. For other respiratory diseases (J95–J99), scenario 1 predicts 10,905 more diagnoses (equivalent to 0.13 diagnoses per 1,000 persons per year, based on the population in 2022 population [42]), while scenario 2 forecasts 7,684 additional diagnoses (0.09 diagnoses per 1,000 persons per year) compared to the baseline scenario. On average, diagnoses occur 0.84 years earlier in scenario 1 and 0.82 years earlier in scenario 2 than in the baseline scenario.

For respiratory diseases affecting the interstitium (J80–J84), scenario 1 shows 3,900 additional diagnoses (0.05 diagnoses per 1,000 persons per year) and scenario 2 2,700 diagnoses (0.03 diagnoses per 1,000 persons per year) more compared to the baseline scenario, with diagnoses occurring 1.12 and 0.85 years earlier, respectively. We find 15,300 more diagnoses (0.19 diagnoses per 1,000 persons per year) of diseases of the liver (K70–K77) in scenario 1 and 10,800 diagnoses more (0.13 diagnoses per 1,000 persons per year) in scenario 2, with diagnoses occurring 0.4




Figure 4. Effect of a 5% reduction in the transition probabilities leading to new onsets of respective diagnosis groups. Reduction in overall death numbers (all-cause mortality from 2022-2030) per reduced diagnosis of 10 diagnosis groups with largest effect on all-cause mortality (a). Per diagnosis group, d , on the y-axis we simulate a scenario where we annually reduce the transition probabilities by 5% to clusters where the probability of being diagnosed with d in the following timestep increases. We compute an ensemble average over 10 simulations. Error bars indicate the standard deviation over these 10 simulations. Ratio of number of prevented overall deaths per prevented overall diagnoses (b). To account for differences in the incidence of both of the reduced diagnosis and potential sequelae, we show the number of reduced deaths in relation to the number of reduced diagnoses (all diagnosis groups) from 2022-2030.

and 0.26 years earlier, respectively.

Organic, including symptomatic, mental disorders demonstrate 19,000 and 13,300 more diagnoses (0.23 and 0.16 diagnoses per 1,000 persons per year) in scenarios 1 and 2, respectively. Diagnoses occur 1.06 and 0.81 years earlier in scenario 1 and 2, respectively.

We examine the contrast in the number of fatalities recorded during the period spanning 2022 to 2030 between the main and the two Covid-19 Shock scenarios (see Figure S4). Notably, there is a rise in deaths attributed to cerebrovascular diseases (I60–I69: 1147-819 deaths), ischaemic heart diseases (I20–I25: 733-538 deaths), other mental and behavioral disorders (F00–F99: 434-291 deaths) and diabetes mellitus (E10–E14: 324-236 deaths) in response to the Covid-19 Shock. In contrast, fatalities from malignant neoplasms exhibit a reduction across in both Covid-19 Shock scenarios. This may be attributed to individuals succumbing to alternative causes of death earlier in the simulation.

3.4 Model quality

Figure S1 represents the incidences of 131 diagnostic groups resulting from both the simulation and the dataset at the end of the calibration period in 2014. We find good agreement between the annual incidences in the data and the simulation with a Pearson correlation coefficient of 0.99 across all diagnoses.

Figure S2 shows a comparative analysis of the dynamics of multimorbidity incidence between the simulation and the dataset. In addition, we present the projection of multimorbidity incidence for the time span 2028-2030, derived from the simulation results. In Figure S2, the number of individuals receiving n diagnoses is expressed as a percentage within each age group. Notably, marginal fluctuations are observed in the evolution of the multimorbidity incidence.

The model effectively captures the dynamics of multimorbidity among the younger age cohorts (0-59). For the three oldest age groups (≥ 60), deviations from the empirical data become apparent when comparing the results for 2012-2014 between the data and the model. In particular, the proportion of highly multimorbid individuals (more than ten diagnoses) is overestimated by a few percentage points in the model. In both, data and model, we see that the distribution of the age-specific multimorbidity incidence remains fairly robust over time, even in the




Figure 5. Difference in the total number of diagnoses (from 2022 to 2030) of the two Covid-19 Shock scenarios compared to the simulation without a shock, respectively (a). Scenario 1 is the pessimistic scenario where we assume a 15 % reduction of the HR of the different diagnosis groups in the y-axis, scenario 2 is the optimistic scenario where we assume a 40 % reduction of due to less severe SARS-CoV-2 variants and vaccines. We find a modest impact on the incidence of SARS-CoV-2 sequelae in both Covid-19 Shock scenarios. Sequelae affecting the respiratory system and the digestive system are the most affected diseases. Difference in the average years until the diagnosis with and without Covid-19 Shock (b). This metric quantifies, how much earlier, on average, are individuals diagnosed with each one of the diagnose groups on the y-axis due to the Covid-19 Shock. The sequelae with the greatest difference in average years until diagnose affect the respiratory, nervous and circulatory system. In addition, organic, including symptomatic, mental disorders (F00-F09) are diagnosed by up to one year earlier.

projections until 2030.

We find that some diagnoses show a substantial inflation in the discrepancy between data and simulation over time. There are 36 diagnostic groups with an absolute error in 2014 exceeding 5% of the 2014 incidence and surpassing 500 cases per annum, as well as those manifesting a 1.3-fold error increase from 2010 to 2014. These diagnoses are excluded from further analysis of changes in incidence.

4 Discussion

We generalize compartmental models as used in epidemiology for modeling infectious diseases in a way that they can be used for long-term predictive modeling of chronic diseases and multimorbidity. Our model uniquely spans 131 diagnostic groups (A00-N99) and 132 multimorbidity patterns. The main idea behind it is to reconstruct individual chronic disease trajectories between different sets of pathological conditions that are represented as "compartments".

The essence of the model is that it can be fully calibrated from actual nationwide observational data. We present a realization of the model that is based on an extensive dataset of hospital diagnoses in Austria from 1997 to 2014. We simulate demographic changes (births, migration, deaths) and the acquisition of new diagnoses based on a multimorbidity network. Calibrated from 2003-2014 data, our model forecasts changes in the incidence of 131 diagnostic groups and their combinations from 2015 to 2030. To our knowledge, the CDTM is the first of its kind by encompassing 131 diagnostic groups spanning diseases from A00-N99 across all age groups. This comprehensive microsimulation framework allows for realistic projections of the incidence of individual diseases and multimorbidity. Additionally, it offers a valuable framework for evaluating the ramifications of various scenarios on the disease burden within the population. This includes prevention efforts, new medication or new diagnostic techniques as well as shocks such as the Covid-19 pandemic.

In our baseline scenario, simulating projected demographic changes (forecasted by the national statistics office), we observe a relative increase in chronic diseases affecting the nervous, genitourinary, metabolic, and cardiovascular systems. In Figure S3, the relative incidence stratified by above/below 65 shows that these diagnoses are more common among individuals above 65. In contrast, the diagnose groups where we observe a decrease in relative incidence, behavioral disorders with onset in childhood (F90-F98) and diseases of appendix (K35-K38) are more common among individuals under 65. These findings align with expectations, further confirming the validity of our model.

The model allows us to examine not only changes in the annual incidence of individual diagnoses, but also changes in the incidence of multimorbidity patterns over time. The CDTM now enables us to provide concrete quantitative estimates for the future development of such multimorbidity clusters under certain conditions. From 2015 to 2030, a 2.7% increase in transitions from clusters of three or more diagnoses to four or more is expected, translating to 97,500 additional individuals in 2030. This indicates a growing complexity of health conditions, necessitating comprehensive healthcare strategies. We observed that the 20 most common multimorbidity clusters that individuals transitioned to in 2015 all showed an increase in relative occurrence (transitioning from one cluster to another) in 2030. 18 out of the 20 most common clusters describe disease patterns including hypertensive diseases (I10-I15), among these are also the most pronounced increases from 2015 to 2030 such as a disease pattern describing hypertensive diseases (I10-I15), other forms of heart disease (I30-I52) and renal failure (N17-N19). This finding is in line with existing literature, which consistently identifies hypertension as one of the most prevalent chronic conditions, either in isolation or in combination with other chronic conditions such as diabetes, hyperlipidemia, ischemic heart disease and chronic kidney disease [43, 44, 45].

Healthcare costs of multimorbidity are difficult to estimate, as the costs of single diseases are not necessarily additive and are likely to depend which diseases co-occur [46]. Using estimates from a systematic review on the costs of multimorbidity and our results on the occurrence of multimorbidity clusters we can approximate an expected cost increase for selected multimorbidity clusters. We estimate increased costs of I\$ 8.7 million (95% CI: I\$ 8.5 million - I\$ 8.9 million) for hypertensive diseases and dorsopathies and I\$ 29.8 million (29.1 million-30.5 million) for hypertensive diseases and arthropathies (average annual direct medical costs of I\$ 13,300 (13,000-13,600 95% CI) for hypertension and musculoskeletal disorders) in 2030 compared to 2015. For hypertensive diseases and diabetes mellitus we estimate an increase of I\$ 13.1 million (12.8 million-13.5 million) (average annual direct medical costs of I\$ 14,300 (13,900-14,700) for hypertension and type 2 diabetes) and an increase of I\$ 37.2 million (36.4 million -38 million) for hypertensive diseases and other forms of heart disease (I\$ 17,900 (17,500-18,300) for

hypertensive diseases and heart/vascular conditions) [46].

The largest differences in the relative occurrence increase between men and women is observed in disease patterns involving renal failure, with men experiencing a larger increase. This aligns with existing literature indicating that while chronic kidney disease (CKD, N18) is more prevalent among women, the combination of CKD with cardiovascular diagnoses is more commonly observed among men [47, 48].

We showcase the use of the model for assessing changes in disease dynamics for scenarios describing decreasing diagnose dynamics, as well as increasing ones.

First we develop a framework to study the effectiveness of mitigation efforts (such as vaccinations or other preventive measures) in reducing causes of death. For each diagnosis, to mimic a prevention measure, we impose a 5% reduction in the transition probability for each individual who would be diagnosed in the following timestep with the respective diagnosis. We also reduce the externally imposed incidence of that diagnosis by 5%. We find the largest reduction in deaths for each prevented diagnose for diseases affecting the circulatory system (hypertensive diseases (I10-I15), ischaemic heart diseases (I20-I25), cerebrovascular diseases (I60-I69) and diseases of veins (I80-I89)), malignant neoplasms (C00-C97), endocrine, nutritional diseases (metabolic disorders (E70-E90), diabetes mellitus (E10-E14) and disorders of the thyroid gland (E00-E07)) and diseases of the respiratory system (acute respiratory infections (J00-J06)). These findings indicate that targeting these diagnoses can effectively promote healthy aging.

Globally, hypertension and metabolic syndrome components have become leading risk factors for disability-adjusted life years (DALYs), especially in women [49]. In Austria, hypertension, smoking and high body mass index are significant risk factors, with many people over 60 suffering from undiagnosed or undertreated hypertension [49, 50, 51]. This condition increases the risk of serious diseases, including heart failure and kidney disease, especially when combined with obesity and diabetes. Prevention of cardiometabolic disorders through better screening, early diagnosis and treatment of modifiable risk factors such as blood pressure, cholesterol, glucose and body weight is essential [52, 53]. Public health efforts to reduce smoking, alcohol consumption, obesity, and infections can significantly reduce the incidence of vascular disease and cancer [9, 52]. New drugs such as GLP-1 RA and SGLT2 inhibitors show promise in reducing hyperglycemia, obesity, cardiovascular disease, and renal failure [54, 55]. These observations are consistent with the results of our model, demonstrating that prevention efforts for these diagnoses are critical to promoting healthy aging and reducing multimorbidity and premature mortality. Better screening for kidney disease and improved management of diabetes and vascular problems will further reduce the risk of serious outcomes, especially in older adults.

An interesting observation is that reduction of thyroid diseases would have great impact on reduction of multimorbidity and death rates. These disorders can be easily detected and treated in most cases. Associations between thyroid function and arrhythmias are well known and a thyroid-cardiac axis has been proposed, which may explain the clinical observation of an association between thyroid function and mortality [56]. Hyperthyroidism and thyreotoxicosis can dramatically increase mortality risk [57]. Both hypothyroidism and hyperthyroidism have been associated with an increased risk of cardiovascular morbidity and mortality in epidemiological studies and meta-analyses. There are several possible pathophysiological mechanisms linking thyroid and cardiovascular disorders such as endothelial dysfunction, blood pressure changes, dyslipidemia, and low-grade systemic inflammation [58]. Venous disorders (I80-I89), like thyroid disorders, are less common causes of death but are prevalent, especially among women, and represent a significant healthcare burden. Our analysis revealed that a reduction of new onsets of diseases of veins leads to a reduction in potentially deadly sequelae. In recent decades, there has been a steady increase in thromboembolic events, including pulmonary embolism, with high rates of recurrence and increased risk of mortality [59]. There are multiple risk factors such as increased age, obesity, prolonged immobility, fractures, hospitalisations and conditions associated with impaired haemostasis such as cancer, diabetes, autoimmune diseases and infections including Covid-19 and pregnancy. It is therefore plausible that a greater focus on possible preventive measures and the reduction of venous disease could imply a large reduction in healthcare costs and morbidity.

As a further demonstration of the versatility of the compartmental disease trajectory model (DCTM), we implement a Covid-19 Shock to estimate the long-term health impact of the Covid-19 pandemic on the Austrian population for both, a pessimistic and an optimistic scenario. Using hazard ratios for being diagnosed with certain sequelae of a SARS-CoV-2 infection drawn from multiple respective cohort studies (see table S2), we study the relative incidence difference of the baseline scenario and the two Covid-19 Shock scenarios. We find the most pronounced increase in incidence (2022-2030) compared to the baseline scenario for other respiratory diseases (43.12-56.17% and 7,700-10,900 diagnoses), for respiratory diseases affecting the interstitium (43.81-55.88% and

2,700-3,900 diagnoses), diseases of the liver (32.13-42.32% and 10,800-15,300 diagnoses) and organic, including symptomatic, mental disorders (28.75%-36.48% and 13,300-19,000 diagnoses). This aligns with our approach, as these sequelae are associated with the highest Hazard Ratios (HRs), except for diseases of the liver. This suggests that the increase in relative incidence of liver diseases is not solely a direct effect of the Covid-19 shock but may also be attributed to it being a sequelae of one of the other conditions. A study of the costs of multimorbidity found average annual direct medical costs of I\$ 36,800 (36,400-37,300) for respiratory and mental health conditions and I\$ 35,000 (34,900-35,300) for respiratory and heart/vascular conditions [46]. We find that on average, individuals are diagnosed with organic, including symptomatic, mental disorders 0.8-1.1 years earlier in Covid-19 Shock scenarios 2 and 1 compared to the baseline scenario. For respiratory diseases affecting the interstitium, individuals are diagnosed up to 0.9-1.1 years earlier. This could potentially lead to an accumulation of more diagnoses as multimorbidity is more compressed towards older ages in simulations without the Covid-19 Shock.

The present study is subject to several limitations. One is limitations in data availability. The hospitalization dataset contains only information until up to 2014 and recent changes, such as medical advances concerning certain diseases, new medication or improvements in diagnostics are not covered. We partially mitigate this issue by evaluating the change in incidence of diagnoses without an error inflation over time, i.e. the difference between data and model incidence (the error) is not changing (in- or decreasing) by more than 1.3 in the last five years of the calibration phase. Another limitation is that it is not possible to distinguish from the data whether a patient did not require further hospitalizations for medical reasons or discontinued his or her treatment for other reasons. The model only examines cumulative health states. It is however reasonable to assume that, especially severe, chronic diseases affect the health state of a patient on a long-term basis. Another shortcoming is the lack of information on outpatient contacts, doctor visits, diagnoses for deaths outside the hospital, socio-economic status and prescribed medications is not available. Finally, the dataset was originally collected for billing purposes, which leads to a potential bias in terms of over- or under-representation of diagnoses.

Data on births, migration, deaths and causes of death are provided by official statistics, 'Statistics Austria'. The forecasts on number of births, migration and deaths (2022 onwards) are taken from the main scenario of Statistics Austria. Data on causes of death are only available up to 2019. We assume that the distribution of death numbers across the different causes remains constant after 2019. Therefore the model doesn't capture changes in death rates by cause. In addition, the projected number of deaths from 2019 onwards assumes the age and sex distribution of deaths by cause in 2019, as the projected number of deaths, stratified by age and sex, are only available for scenarios that already include the effect of the Covid-19 pandemic. This means that the model accurately captures the total number of deaths, but it does not take into account the different trends in the age and sex distributions.

On a methodological level, we make two important adjustments to the multimorbidity network by Haug *et al.* (2020) [22]. First, we compute new probabilities of being diagnosed with disease, d , given an assignment to cluster, c , to calibrate the model at initialization to the incidences in the data in 2003. Second, we rescale the age- and sex-dependent transition probabilities overall (same scaling factor for each diagnosis) by an age-dependent factor α , simulate from 2003-2014 and externally assign the difference per age-, sex- and diagnose group to calculate rates for the forecast period. Using the transition probabilities without adjustment does capture the development of incidence per diagnosis group in the calibration period 2003-2014. However, the use of unadjusted transition probabilities results in the model not correctly capturing the dynamics of multimorbidity (number of individuals diagnosed with 2 or more diseases) in the data. Note, that our population cohort differs from the cohort used to construct the network in [22], which consisted of individuals with no recorded diagnoses in 1997-2002. The population cohort studied here includes these individuals, hence adjustments in the transition rates are necessary.

The implementation of the Covid-19 Shock relies on assumptions taken over from the literature. These should be considered when interpreting the results. We assume, that each individual in the model population has been infected once by 2022. The HRs used are from different retrospective cohort studies [60, 61, 62, 63] which were mainly conducted early-on in the pandemic. Therefore, we assume a reduction of the HRs by 15% (scenario 1) and 40% (scenario 2) due to less severe virus variants and vaccination rollouts, respectively. We provide an estimated range of the impact of the pandemic on the healthcare burden and not exact incidence forecasts. Further studies on sequelae of SARS-CoV-2 can be used to make more precise estimates on how the Covid-19 pandemic affects the healthcare system in terms of chronic disease incidence and multimorbidity.

Our findings demonstrate that targeted prevention efforts can significantly reduce multimorbidity and associated healthcare costs. Additional research is required to investigate the progression of multimorbidity, particularly

in the context of an aging population and socioeconomic factors. It has been found that the onset of multimorbidity occurs 10 to 15 years earlier for people living in socioeconomically disadvantaged regions [64, 65]. Future research should also explore the application of this model in different countries and its adaptability to other health shocks, such as climate-related events, to further understand the dynamics of multimorbidity.

Author Contributions

PK conceptualized and supervised the project. PK and KL devised the analytic methods. KL carried out the analysis and produced the plots and graphics. KL and PK wrote the first draft of the manuscript. AK-W and ST made critical comments regarding the manuscript. AK-W contributed medical expertise regarding the medical interpretation of the findings and in developing medical hypotheses. AK-W, ST, KL and PK conducted reviewing and editing of the manuscript. All authors read and approved the final manuscript.

Data Availability Statement

This study was conducted using a pseudonymized research dataset only accessible for selected research partners under strict data protection regulations. Data on disease cluster and sex- and age-stratified transition rates between the different clusters is available from the authors upon request.

Competing Interests Statement

The authors have declared that no competing interests exist.

Code Availability

The underlying code for this study [and training/validation datasets] is not publicly available but may be made available to qualified researchers on reasonable request from the corresponding author.

References

- [1] World Health Organization. *Global Health Estimates: Life expectancy and leading causes of death and disability*. URL: <https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates/ghe-life-expectancy-and-healthy-life-expectancy>.
- [2] Our World in Data. *Life Expectancy*. URL: <https://ourworldindata.org/life-expectancy>.
- [3] Statistics Austria. *Healthy life expectancy*. 2024. URL: <https://www.statistik.at/en/statistics/population-and-society/health/health-status/healthy-life-expectancy>.
- [4] Statistics Austria. *Population projections for Austria and federal states*. 2024. URL: <https://www.statistik.at/en/statistics/population-and-society/population/demographische-prognosen/population-projections-for-austria-and-federal-states>.
- [5] Norman Mukasa and Ronald Schoenmaeckers. *Ageing policies – access to services in different Member States. Country study on Austria (Annex I)*. en. Tech. rep. 2021, p. 36.
- [6] V Raleigh. “Trends in life expectancy in EU and other OECD countries: Why are improvements slowing?” In: 108 (2019). DOI: <https://doi.org/10.1787/223159ab-en>.
- [7] Statistics Austria. *Healthy Life Years at birth since 1978 by self-perceived health status and sex - in years*. Nov. 2022. URL: <https://www.statistik.at/en/statistics/population-and-society/health/health-status/healthy-life-expectancy>.
- [8] European Observatory on Health Systems and Policies. *Austria: Country Health Profile 2021*. Tech. rep. 2021. URL: <https://eurohealthobservatory.who.int/publications/m/austria-country-health-profile-2021>.
- [9] Florian Bachner et al. *Health System Review 2018*. en. Tech. rep. 2018.
- [10] Cheng Hwee Soh et al. “Morbidity Measures Predicting Mortality in Inpatients: A Systematic Review”. en. In: *Journal of the American Medical Directors Association* 21.4 (Apr. 2020), 462–468.e7. ISSN: 15258610. DOI: 10.1016/j.jamda.2019.12.001. URL: <https://linkinghub.elsevier.com/retrieve/pii/S1525861019308400> (visited on 10/24/2023).
- [11] Christopher J M Whitty et al. “Rising to the challenge of multimorbidity”. en. In: *BMJ* (Jan. 2020), p. 16964. ISSN: 1756-1833. DOI: 10.1136/bmj.16964. URL: <https://www.bmj.com/lookup/doi/10.1136/bmj.16964> (visited on 10/24/2023).
- [12] Jonathan Pearson-Stuttard, Majid Ezzati, and Edward W Gregg. “Multimorbidity—a defining challenge for health systems”. In: 4 (2019), e599–e600. DOI: 10.1016/S2468-2667(19)30222-1.
- [13] Alessandra Marengoni et al. “Prevalence of Chronic Diseases and Multimorbidity Among the Elderly Population in Sweden”. en. In: *American Journal of Public Health* 98.7 (July 2008), pp. 1198–1200. ISSN: 0090-0036, 1541-0048. DOI: 10.2105/AJPH.2007.121137. URL: <https://ajph.aphapublications.org/doi/full/10.2105/AJPH.2007.121137> (visited on 10/13/2022).
- [14] Ran Zhang et al. “Prevalence and patterns of multimorbidity among the elderly in China: a cross-sectional study using national survey data”. en. In: *BMJ Open* 9.8 (Aug. 2019), e024268. ISSN: 2044-6055, 2044-6055. DOI: 10.1136/bmjopen-2018-024268. URL: <https://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2018-024268> (visited on 10/13/2022).
- [15] Hendrik van den Bussche et al. “Which chronic diseases and disease combinations are specific to multimorbidity in the elderly? Results of a claims data based cross-sectional study in Germany”. en. In: *BMC Public Health* 11.1 (Dec. 2011), p. 101. ISSN: 1471-2458. DOI: 10.1186/1471-2458-11-101. URL: <https://bmcpublichealth.biomedcentral.com/articles/10.1186/1471-2458-11-101> (visited on 10/13/2022).
- [16] Martin Fortin, Catherine Hudon, and Jeannie Haggerty. “RPerseearvchaalrteicnle ce estimates of multimorbidity: a comparative study of two sources”. en. In: (2010), p. 6.
- [17] Anna J Koné Pefoyo et al. “The increasing burden and complexity of multimorbidity”. en. In: (2015), p. 11.

- [18] Miguel J. Divo, Carlos H. Martinez, and David M. Mannino. “Ageing and the epidemiology of multimorbidity”. en. In: *European Respiratory Journal* 44.4 (Oct. 2014), pp. 1055–1068. ISSN: 0903-1936, 1399-3003. DOI: 10.1183/09031936.00059814. URL: <http://erj.ersjournals.com/lookup/doi/10.1183/09031936.00059814> (visited on 10/13/2022).
- [19] Iris Szu-Szu Ho et al. “Examining variation in the measurement of multimorbidity in research: a systematic review of 566 studies”. en. In: *The Lancet Public Health* 6.8 (Aug. 2021), e587–e597. ISSN: 24682667. DOI: 10.1016/S2468-2667(21)00107-9. URL: <https://linkinghub.elsevier.com/retrieve/pii/S2468266721001079> (visited on 10/13/2022).
- [20] Kathryn Nicholson, José Almirall, and Martin Fortin. “The measurement of multimorbidity.” In: *Health Psychology* 38.9 (2019). Place: US Publisher: American Psychological Association, pp. 783–790. ISSN: 1930-7810(Electronic),0278-6133(Print). DOI: 10.1037/hea0000739.
- [21] Anna Chmiel, Peter Klimek, and Stefan Thurner. “Spreading of diseases through comorbidity networks across life and gender”. en. In: *New Journal of Physics* 16.11 (Nov. 2014), p. 115013. ISSN: 1367-2630. DOI: 10.1088/1367-2630/16/11/115013. URL: <https://iopscience.iop.org/article/10.1088/1367-2630/16/11/115013> (visited on 10/24/2023).
- [22] Nils Haug et al. “High-risk multimorbidity patterns on the road to cardiovascular mortality”. en. In: *BMC Medicine* 18.1 (Dec. 2020), p. 44. ISSN: 1741-7015. DOI: 10.1186/s12916-020-1508-1. URL: <https://bmcmmedicine.biomedcentral.com/articles/10.1186/s12916-020-1508-1> (visited on 04/11/2022).
- [23] César A. Hidalgo et al. “A Dynamic Network Approach for the Study of Human Phenotypes”. en. In: *PLoS Computational Biology* 5.4 (Apr. 2009). Ed. by Lauren Ancel Meyers, e1000353. ISSN: 1553-7358. DOI: 10.1371/journal.pcbi.1000353. URL: <https://dx.plos.org/10.1371/journal.pcbi.1000353> (visited on 10/31/2023).
- [24] Anders Boeck Jensen et al. “Temporal disease trajectories condensed from population-wide registry data covering 6.2 million patients”. en. In: *NATURE COMMUNICATIONS* (2014).
- [25] Eugene Jeong et al. “Network-based analysis of diagnosis progression patterns using claims data”. en. In: *Scientific Reports* 7.1 (Nov. 2017), p. 15561. ISSN: 2045-2322. DOI: 10.1038/s41598-017-15647-4. URL: <https://www.nature.com/articles/s41598-017-15647-4> (visited on 10/31/2023).
- [26] Babak Fotouhi et al. “Statistical methods for constructing disease comorbidity networks from longitudinal inpatient data”. en. In: *Applied Network Science* 3.1 (Dec. 2018), p. 46. ISSN: 2364-8228. DOI: 10.1007/s41109-018-0101-4. URL: <https://appliednetsci.springeropen.com/articles/10.1007/s41109-018-0101-4> (visited on 11/08/2023).
- [27] Francisco S Roque et al. “Using Electronic Patient Records to Discover Disease Correlations and Stratify Patient Cohorts”. en. In: *PLoS Computational Biology* 7.8 (2011).
- [28] Jessica X Hu et al. “A Large-Cohort, Longitudinal Study Determines Precancer Disease Routes across Different Cancer Types”. en. In: *Cancer Research* Volume 79 Issue 4 (2019).
- [29] Amalie D Haue, JJ Armenteros, and P.C. Holm. “Temporal patterns of multi-morbidity in 570157 ischemic heart disease patients: a nationwide cohort study”. en. In: 21 (2022). DOI: <https://doi.org/10.1186/s12933-022-01527-3>.
- [30] Mette K Beck et al. “Diagnosis trajectories of prior multi-morbidity predict sepsis mortality”. en. In: *Scientific Reports* 6, 36624 (2016). DOI: <https://doi.org/10.1038/srep36624>.
- [31] Alexia Giannoula et al. “Identifying temporal patterns in patient disease trajectories using dynamic time warping: A population-based study”. en. In: *Scientific Reports* 8, 4216 (2018). DOI: <https://doi.org/10.1038/s41598-018-22578-1>.
- [32] Alexia Giannoula et al. “A system-level analysis of patient disease trajectories based on clinical, phenotypic and molecular similarities”. en. In: 37(10) (2020). DOI: 10.1093/bioinformatics/btaa964.
- [33] Alexia Giannoula et al. “Identifying Temporal Patterns in Healthcare Service-Use Trajectories of Long-Term Breast Cancer Survivors”. In: *Proceedings of the 11th Annual Symposium on Global Cancer Research; Closing the Research-to-Implementation Gap* (2023).

- [34] G Savcicens et al. “Using sequences of life-events to predict human lives”. In: 4, 43-56 (2024). DOI: <https://doi.org/10.1038/s43588-023-00573-5>.
- [35] Sandra H van Oostrom et al. “Multimorbidity and comorbidity in the Dutch population – data from general practices”. en. In: *BMC Public Health* 12.1 (Dec. 2012), p. 715. ISSN: 1471-2458. DOI: 10.1186/1471-2458-12-715. URL: <https://bmcpublihealth.biomedcentral.com/articles/10.1186/1471-2458-12-715> (visited on 10/13/2022).
- [36] Annemarie A. Uijen and Eloy H. van de Lisdonk. “Multimorbidity in primary care: Prevalence and trend over the last 20 years”. en. In: *European Journal of General Practice* 14.sup1 (Jan. 2008), pp. 28–32. ISSN: 1381-4788, 1751-1402. DOI: 10.1080/13814780802436093. URL: <http://www.tandfonline.com/doi/full/10.1080/13814780802436093> (visited on 09/05/2022).
- [37] Christopher Harrison et al. “The prevalence of complex multimorbidity in Australia”. en. In: *Australian and New Zealand Journal of Public Health* 40.3 (June 2016), pp. 239–244. ISSN: 13260200. DOI: 10.1111/1753-6405.12509. URL: <https://onlinelibrary.wiley.com/doi/10.1111/1753-6405.12509> (visited on 10/13/2022).
- [38] Andrew Kingston, Adelina Comas-Herrera, and Carol Jagger. “Forecasting the care needs of the older population in England over the next 20 years: estimates from the Population Ageing and Care Simulation (PACSim) modelling study”. en. In: *The Lancet Public Health* 3.9 (Sept. 2018), e447–e455. ISSN: 24682667. DOI: 10.1016/S2468-2667(18)30118-X. URL: <https://linkinghub.elsevier.com/retrieve/pii/S246826671830118X> (visited on 10/13/2022).
- [39] Andrew Kingston et al. “Projections of multi-morbidity in the older population in England to 2035: estimates from the Population Ageing and Care Simulation (PACSim) model”. en. In: *Age and Ageing* 47.3 (May 2018), pp. 374–380. ISSN: 0002-0729, 1468-2834. DOI: 10.1093/ageing/afx201. URL: <https://academic.oup.com/ageing/article/47/3/374/4815738> (visited on 09/13/2023).
- [40] Bundesministerium für Soziales, Gesundheit, Pflege und Konsumentenschutz (BMSGPK). *COVID-19: Daten Covid19-Fälle je Altersgruppe*. 2024. URL: <https://www.data.gv.at/katalog/dataset/covid-19-daten-covid19-faelle-je-altergruppe>.
- [41] Statistics Austria. *Causes of death*. 2024. URL: <https://www.statistik.at/en/statistics/population-and-society/population/deaths/causes-of-death> (visited on 11/01/2024).
- [42] Statistics Austria. *Projected population structure for Austria 2020-2080*. Nov. 2022. URL: <https://www.statistik.at/en/statistics/population-and-society/population/demographische-prognosen/population-projecions-for-austria-and-federal-states>.
- [43] Inge Kirchberger et al. “Patterns of Multimorbidity in the Aged Population. Results from the KORA-Age Study”. en. In: *PLoS ONE* 7.1 (2012).
- [44] Marcel E. Salive. “Multimorbidity in Older Adults”. In: 35 (2013). DOI: 10.1093/epirev/mxs009.
- [45] Grace Hawthorne et al. “Multimorbidity prevalence and patterns in chronic kidney disease: findings from an observational multicentre UK cohort study”. en. In: *International Urology and Nephrology* 55.8 (Feb. 2023), pp. 2047–2057. ISSN: 1573-2584. DOI: 10.1007/s11255-023-03516-1. URL: <https://link.springer.com/10.1007/s11255-023-03516-1> (visited on 02/08/2024).
- [46] Phuong Bich Tran et al. “Costs of multimorbidity: a systematic review and meta-analyses”. en. In: 20, 234 (2022). DOI: <https://doi.org/10.1186/s12916-022-02427-9>.
- [47] Stephanie M. Toth-Manikowski et al. “Sex Differences in Cardiovascular Outcomes in CKD: Findings From the CRIC Study”. en. In: *American Journal of Kidney Diseases* 78.2 (Aug. 2021), 200–209.e1. ISSN: 02726386. DOI: 10.1053/j.ajkd.2021.01.020. URL: <https://linkinghub.elsevier.com/retrieve/pii/S0272638621005126> (visited on 02/08/2024).
- [48] Kaitlin J. Mayne, Michael K. Sullivan, and Jennifer S. Lees. “Sex and gender differences in the management of chronic kidney disease and hypertension”. en. In: *Journal of Human Hypertension* 37.8 (June 2023), pp. 649–653. ISSN: 1476-5527. DOI: 10.1038/s41371-023-00843-9. URL: <https://www.nature.com/articles/s41371-023-00843-9> (visited on 02/08/2024).

- [49] Institute for Health Metrics and Evaluation. *Global Disease Burden (GBD Compare)*. URL: <https://vizhub.healthdata.org/gbd-compare/> (visited on 05/02/2024).
- [50] Katherine T. Mills et al. “Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies From 90 Countries”. en. In: *Circulation* 134.6 (Aug. 2016), pp. 441–450. ISSN: 0009-7322, 1524-4539. DOI: 10.1161/CIRCULATIONAHA.115.018912. URL: <https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.115.018912> (visited on 02/09/2024).
- [51] A Sillars et al. “Sex differences in the association of risk factors for heart failure incidence and mortality”. In: 106(3) (2020), pp. 203–12. DOI: 10.1136/heartjnl-2019-314878.
- [52] Ophira Ginsburg et al. “Women, power, and cancer: a Lancet Commission”. en. In: *The Lancet* 402.10417 (Dec. 2023), pp. 2113–2166. ISSN: 01406736. DOI: 10.1016/S0140-6736(23)01701-4. URL: <https://linkinghub.elsevier.com/retrieve/pii/S0140673623017014> (visited on 01/15/2024).
- [53] The Global Cardiovascular Risk Consortium et al. “Global Effect of Modifiable Risk Factors on Cardiovascular Disease and Mortality”. en. In: *New England Journal of Medicine* 389.14 (Oct. 2023), pp. 1273–1285. ISSN: 0028-4793, 1533-4406. DOI: 10.1056/NEJMoa2206916. URL: <http://www.nejm.org/doi/10.1056/NEJMoa2206916> (visited on 02/09/2024).
- [54] AK Singh and Singh. “Gender difference in cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in type 2 diabetes: A systematic review and meta-analysis of cardio-vascular outcome trials”. In: 14(3).181-7 (2020). DOI: 10.1016/j.dsx.2020.02.012.
- [55] Daniel Tobias Michaeli et al. “Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention”. en. In: *American Journal of Cardiovascular Drugs* 23.5 (Sept. 2023), pp. 477–495. ISSN: 1175-3277, 1179-187X. DOI: 10.1007/s40256-023-00594-5. URL: <https://link.springer.com/10.1007/s40256-023-00594-5> (visited on 02/09/2024).
- [56] Patrick Müller, Melvin Khee-Shing Leow, and Johannes W. Dietrich. “Minor perturbations of thyroid homeostasis and major cardiovascular endpoints—Physiological mechanisms and clinical evidence”. en. In: *Frontiers in Cardiovascular Medicine* 9 (Aug. 2022), p. 942971. ISSN: 2297-055X. DOI: 10.3389/fcvm.2022.942971. URL: <https://www.frontiersin.org/articles/10.3389/fcvm.2022.942971/full> (visited on 01/15/2024).
- [57] Stavroula A. Paschou et al. “Thyroid disorders and cardiovascular manifestations: an update”. en. In: *Endocrine* 75.3 (Mar. 2022), pp. 672–683. ISSN: 1355-008X, 1559-0100. DOI: 10.1007/s12020-022-02982-4. URL: <https://link.springer.com/10.1007/s12020-022-02982-4> (visited on 01/15/2024).
- [58] P Poredos et al. “Endocrine Disorders and Peripheral Arterial Disease - A Series of Reviews Cushing Syndrome-Cortisol Excess”. In: *Curr Vasc Pharmacol* (Nov. 2023). DOI: 10.2174/0115701611272145231106053914.
- [59] Sean B. Smith et al. “Analysis of National Trends in Admissions for Pulmonary Embolism”. en. In: *Chest* 150.1 (July 2016), pp. 35–45. ISSN: 00123692. DOI: 10.1016/j.chest.2016.02.638. URL: <https://linkinghub.elsevier.com/retrieve/pii/S0012369216012575> (visited on 01/15/2024).
- [60] Ziyad Al-Aly, Yan Xie, and Benjamin Bowe. “High-dimensional characterization of post-acute sequelae of COVID-19”. en. In: *Nature* 594.7862 (June 2021), pp. 259–264. ISSN: 0028-0836, 1476-4687. DOI: 10.1038/s41586-021-03553-9. URL: <http://www.nature.com/articles/s41586-021-03553-9> (visited on 04/20/2022).
- [61] Sarah E Daugherty et al. “Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study”. en. In: *BMJ* (May 2021), n1098. ISSN: 1756-1833. DOI: 10.1136/bmj.n1098. URL: <https://www.bmj.com/lookup/doi/10.1136/bmj.n1098> (visited on 04/11/2022).
- [62] Evan Xu, Yan Xie, and Ziyad Al-Aly. “Long-term neurologic outcomes of COVID-19”. en. In: *Nature Medicine* (Sept. 2022). ISSN: 1078-8956, 1546-170X. DOI: 10.1038/s41591-022-02001-z. URL: <https://www.nature.com/articles/s41591-022-02001-z> (visited on 10/04/2022).
- [63] Yan Xie, Evan Xu, and Ziyad Al-Aly. “Risks of mental health outcomes in people with covid-19: cohort study”. en. In: *BMJ* (Feb. 2022), e068993. ISSN: 1756-1833. DOI: 10.1136/bmj-2021-068993. URL: <https://www.bmj.com/lookup/doi/10.1136/bmj-2021-068993> (visited on 04/11/2022).

- [64] Karen Barnett et al. “Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study”. en. In: *The Lancet* 380.9836 (July 2012), pp. 37–43. ISSN: 01406736. DOI: 10.1016/S0140-6736(12)60240-2. URL: <https://linkinghub.elsevier.com/retrieve/pii/S0140673612602402> (visited on 11/17/2022).
- [65] Søren T. Skou et al. “Multimorbidity”. en. In: *Nature Reviews Disease Primers* 8.1 (July 2022), p. 48. ISSN: 2056-676X. DOI: 10.1038/s41572-022-00376-4. URL: <https://www.nature.com/articles/s41572-022-00376-4> (visited on 09/13/2023).
- [66] Evan Xu, Yan Xie, and Ziyad Al-Aly. “Long-term gastrointestinal outcomes of COVID-19”. en. In: *Nature Communications* 14.1 (Mar. 2023), p. 983. ISSN: 2041-1723. DOI: 10.1038/s41467-023-36223-7. URL: <https://www.nature.com/articles/s41467-023-36223-7> (visited on 09/13/2023).

Supplementary Information

Construction of Multimorbidity Network

The multimorbidity network underlying the compartmental disease trajectory model (CDTM) is developed by Haug *et al.* (2020) [22] based on the same dataset of hospital diagnoses from 1997-2014 in Austria.

To construct the network, Haug *et al.* (2020) extracted from the dataset all diagnoses with codes in the range A00 to N99 (1074 codes) for a specific subset of individuals. This subset consists of individuals who did not receive a diagnosis between 1997 and 2002, but did receive a diagnosis between 2003 and 2014, to ensure that only patients who can be assumed to be healthy are included. The diagnoses are grouped into 131 diagnostic groups defined by the WHO (see table S1). Each health state per patient and year is coded as a binary vector with 131 entries. An entry with a value of 1 indicates that the individual was diagnosed with the respective diagnosis group, while a value of 0 indicates the absence of such a diagnosis. Note that these diagnoses are cumulative, indicating that an individual remains diagnosed with a disease throughout the observation period, as the dataset lacks information on the resolution or recovery of diagnoses over time. A hierarchical clustering algorithm (DIVCLUS-T [**divclus**]) identified 132 multimorbidity patterns. Each cluster, multimorbidity pattern, contains a set of diseases with which each patient in that cluster was diagnosed (inclusion criteria) and a set of diseases with which each patient in that cluster was not diagnosed (exclusion criteria). Each cluster is assigned a vector of 131 probabilities, with probability 0 for exclusion criteria and probability 1 for inclusion criteria. Disease groups that are neither inclusion nor exclusion criteria have probabilities between 0 and 1. For each pair of clusters, there exists a disease that is an inclusion in one cluster and an exclusion in the other. Since a patient's health status includes all the diseases the patient has been diagnosed with, cluster transitions are only possible in one direction. The clusters, multimorbidity patterns, serve as nodes in a multiplexed network, with directed edges representing transition probabilities between these patterns. Each layer of the network corresponds to a specific age and sex group. The directed edges between two clusters k and j are weighted based on the age (a) and sex (g) dependent probabilities ($q_{g,a,k,j}$) of transitioning from one cluster to another within a single time step. The nodes and links in this multilayer network form the basis for the states (compartments) and their transitions in the CDTM.

Table S1. 131 Disease Groups as defined by the WHO.

ID	ICD-10	Description
0	A00-A09	Intestinal infectious diseases
1	A15-A19	Tuberculosis
2	A20-A28	Certain zoonotic bacterial diseases
3	A30-A49	Other bacterial diseases
4	A50-A64	Infections with a predominantly sexual mode of transmission
5	A65-A69	Other spirochaetal diseases
6	A70-A74	Other diseases caused by chlamydiae
7	A75-A79	Rickettsioses
8	A80-A91	Viral infections of the central nervous system
9	A92-A99	Arthropod-borne viral fevers and viral haemorrhagic fevers
10	B00-B09	Viral infections characterized by skin and mucous membrane lesions
11	B15-B19	Viral hepatitis
12	B20-B24	Human immunodeficiency virus [HIV] disease
13	B25-B34	Other viral diseases
14	B35-B49	Mycoses
15	B50-B64	Protozoal diseases
16	B65-B83	Helminthiases
17	B85-B89	Pediculosis, acariasis and other infestations
18	B90-B94	Sequelae of infectious and parasitic diseases
19	B95-B97	Bacterial, viral and other infectious agents
20	B99-B99	Other infectious diseases
21	C00-C97	Malignant neoplasms
22	D00-D09	In situ neoplasms
23	D10-D36	Benign neoplasms
24	D37-D48	Neoplasms of uncertain or unknown behaviour
25	D50-D53	Nutritional anaemias
26	D55-D59	Haemolytic anaemias
27	D60-D64	Aplastic and other anaemias
28	D65-D69	Coagulation defects, purpura and other haemorrhagic conditions
29	D70-D77	Other diseases of blood and blood-forming organs
30	D80-D89	Certain disorders involving the immune mechanism
31	E00-E07	Disorders of thyroid gland
32	E10-E14	Diabetes mellitus
33	E15-E16	Other disorders of glucose regulation and pancreatic internal secretion
34	E20-E35	Disorders of other endocrine glands
35	E40-E46	Malnutrition
36	E50-E64	Other nutritional deficiencies
37	E65-E68	Obesity and other hyperalimentation
38	E70-E90	Metabolic disorders
39	F00-F09	Organic, including symptomatic, mental disorders
40	F10-F19	Mental and behavioral disorders due to psychoactive substance use
41	F20-F29	Schizophrenia, schizotypal and delusional disorders
42	F30-F39	Mood [affective] disorders
43	F40-F48	Neurotic, stress-related and somatoform disorders
44	F50-F59	Behavioral syndromes associated with physiological disturbances and physical factors
45	F60-F69	Disorders of adult personality and behaviour
46	F70-F79	Mental retardation
47	F80-F89	Disorders of psychological development
48	F90-F98	Behavioral and emotional disorders with onset usually occurring in childhood and adolescence
49	F99-F99	Unspecified mental disorder
50	G00-G09	Inflammatory diseases of the central nervous system
51	G10-G13	Systemic atrophies primarily affecting the central nervous system
52	G20-G26	Extrapyramidal and movement disorders
53	G30-G32	Other degenerative diseases of the nervous system
54	G35-G37	Demyelinating diseases of the central nervous system
55	G40-G47	Episodic and paroxysmal disorders
56	G50-G59	Nerve, nerve root and plexus disorders
57	G60-G64	Polyneuropathies and other disorders of the peripheral nervous system
58	G70-G73	Diseases of myoneural junction and muscle
59	G80-G83	Cerebral palsy and other paralytic syndromes
60	G90-G99	Other disorders of the nervous system
61	H00-H06	Disorders of eyelid, lacrimal system and orbit
62	H10-H13	Disorders of conjunctiva
63	H15-H22	Disorders of sclera, cornea, iris and ciliary body
64	H25-H28	Disorders of lens

65	H30-H36	Disorders of choroid and retina
66	H40-H42	Glaucoma
67	H43-H45	Disorders of vitreous body and globe
68	H46-H48	Disorders of optic nerve and visual pathways
69	H49-H52	Disorders of ocular muscles, binocular movement, accommodation and refraction
70	H53-H54	Visual disturbances and blindness
71	H55-H59	Other disorders of eye and adnexa
72	H60-H62	Diseases of external ear
73	H65-H75	Diseases of middle ear and mastoid
74	H80-H83	Diseases of inner ear
75	H90-H95	Other disorders of ear
76	I00-I02	Acute rheumatic fever
77	I05-I09	Chronic rheumatic heart diseases
78	I10-I15	Hypertensive diseases
79	I20-I25	Ischaemic heart diseases
80	I26-I28	Pulmonary heart disease and diseases of pulmonary circulation
81	I30-I52	Other forms of heart disease
82	I60-I69	Cerebrovascular diseases
83	I70-I79	Diseases of arteries, arterioles and capillaries
84	I80-I89	Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified
85	I95-I99	Other and unspecified disorders of the circulatory system
86	J00-J06	Acute upper respiratory infections
87	J09-J18	Influenza and pneumonia
88	J20-J22	Other acute lower respiratory infections
89	J30-J39	Other diseases of upper respiratory tract
90	J40-J47	Chronic lower respiratory diseases
91	J60-J70	Lung diseases due to external agents
92	J80-J84	Other respiratory diseases principally affecting the interstitium
93	J85-J86	Suppurative and necrotic conditions of lower respiratory tract
94	J90-J94	Other diseases of pleura
95	J95-J99	Other diseases of the respiratory system
96	K00-K14	Diseases of oral cavity, salivary glands and jaws
97	K20-K31	Diseases of oesophagus, stomach and duodenum
98	K35-K38	Diseases of appendix
99	K40-K46	Hernia
100	K50-K52	Noninfective enteritis and colitis
101	K55-K63	Other diseases of intestines
102	K65-K67	Diseases of peritoneum
103	K70-K77	Diseases of liver
104	K80-K87	Disorders of gallbladder, biliary tract and pancreas
105	K90-K93	Other diseases of the digestive system
106	L00-L08	Infections of the skin and subcutaneous tissue
107	L10-L14	Bullous disorders
108	L20-L30	Dermatitis and eczema
109	L40-L45	Papulosquamous disorders
110	L50-L54	Urticaria and erythema
111	L55-L59	Radiation-related disorders of the skin and subcutaneous tissue
112	L60-L75	Disorders of skin appendages
113	L80-L99	Other disorders of the skin and subcutaneous tissue
114	M00-M25	Arthropathies
115	M30-M36	Systemic connective tissue disorders
116	M40-M54	Dorsopathies
117	M60-M79	Soft tissue disorders
118	M80-M94	Osteopathies and chondropathies
119	M95-M99	Other disorders of the musculoskeletal system and connective tissue
120	N00-N08	Glomerular diseases
121	N10-N16	Renal tubulo-interstitial diseases
122	N17-N19	Renal failure
123	N20-N23	Urolithiasis
124	N25-N29	Other disorders of kidney and ureter
125	N30-N39	Other diseases of urinary system
126	N40-N51	Diseases of male genital organs
127	N60-N64	Disorders of breast
128	N70-N77	Inflammatory diseases of female pelvic organs
129	N80-N98	Noninflammatory disorders of female genital tract
130	N99-N99	Other disorders of the genitourinary system




Figure S1. Incidence of the 131 diagnose groups in simulation year 2014 and incidence of the 131 diagnose groups in the data, 2014.




Figure S2. Multimorbidity Incidence observed in the dataset and the simulation results. Each figure shows the proportion of individuals with k diagnoses (ranging from 1-3 to more than 10 diagnoses) among all individuals being diagnosed with at least one diagnose in the respective age groups. The figures a) and b) in the top panel show the incidence of multimorbidity in the dataset for the periods 2004-2006 and 2012-2014, respectively. In the bottom panel, the figure c), d) and e) show the multimorbidity incidence in the simulation result for the time periods 2004-2006, 2012-2014 and 2028-2030, respectively. Comparing a) and c), and b) and d) shows that the model represents the multimorbidity trends well in the younger age groups (from 0 to 59). The model shows deviations from the resulting incidence in the data in respect to the last three age groups, especially for individuals aged 80 years or older. The proportion of individuals in the simulation result with 1-3 diagnoses in the first six age groups ranges from 93 % for individuals aged 20-29 to 74 % for individuals aged 50-59 for the time period 2004-2006. In the dataset, we observe 95 % for individuals aged 20-29 to 76 % for individuals aged 50-59. The mean absolute deviation for all k diagnoses in these age groups is 1%. For individuals aged 60 years or older the proportion of individuals with 1-3 diagnoses ranges from 66 % to 68 % in the simulation result and 68 % to 50 % in the dataset. The mean absolute deviation for all k diagnoses in these age groups is 6 %. The simulation yields among the first six age groups a range of proportion of individuals with 1-3 diagnoses from 91 % (20-29 years) to 68 % (50-59 years) in the time period 2014-2016. In the dataset we observe 95 % (20-29 years) to 81 % (50-59 years) for the same timeframe. The mean absolute deviation for all k diagnoses in these age groups is 3 %. For the last three age groups the simulation results in a proportion of individuals with 1-3 diagnoses ranging from 61 % (60-69 years) to 71 % (≥ 80 years) whereas in the data we find a range from 74 % (60-69 years) to 59 % (≥ 80 years). The mean absolute deviation for all k diagnoses in these age groups is 6 %.




Figure S3. Relative incidence in 2014 (from dataset) of the diagnoses shown in Figure 2. Relative to number of individuals diagnosed in that year (stratified by younger or older than 65).




Figure S4. Impact of the Covid Shock Scenarios on death numbers. The figure illustrates the difference in death numbers from 2022 to 2030. There is an increase especially in death causes related to diseases affecting the circulatory system. We observe a decrease in deaths due to malignant neoplasms. This can be attributed to individuals succumbing to other diseases earlier in the simulation.

Disease	Disease Group	Hazard Ratio	Source
Anxiety Disorder	Neurotic, stress-related and somatoform disorders (F40-F48)	1.38	[62]
Depressive Disorder	Mood [affective] disorders (F30-F39)	1.44	[62]
Ischemic stroke	Cerebrovascular diseases (I60-I69)	1.5	[62]
Myocarditis	Other forms of heart disease (I30-I52)	5.38	[60]
Myocardial Infarction	Ischaemic heart diseases (I20-I25)	1.63	[60]
Angina	Ischaemic heart diseases (I20-I25)	1.52	[60]
Heart Failure	Other forms of heart disease (I30-I52)	1.62	[60]
Non-ischemic Cardiomyopathy	Other forms of heart disease (I30-I52)	2.45	[60]
Cardiac Arrest	Other forms of heart disease (I30-I52)	2.43	[60]
Pulmonary Embolism	Pulmonary heart disease and diseases of pulmonary circulation (I26-I28)	2.93	[60]
Migraine	Episodic and paroxysmal disorders (G40-G47)	1.21	[62]
Peripheral Neuropathy	Polyneuropathies and other disorders of the peripheral nervous system (G60-G64)	1.34	[62]
Encephalopathy	Other disorders of the nervous system (G90-G99)	1.82	[61]
Seizure	Episodic and paroxysmal disorders (G40-G47)	1.8	[62]
Dementia	Other degenerative diseases of the nervous system (G30-G32) Organic, including symptomatic, mental disorders (F00-F09)	4.00	[61]
Type 2 Diabetes	Diabetes mellitus (E10-E14)	1.4	[63]
Liver Test Abnormality	Diseases of liver (K70-K77)& Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified (I80-I89)& Viral hepatitis (B15-B19)	1.70	[61]
Kidney Injury	Hypertensive diseases (I10-I15)& Renal failure (N17-N19)	1.53	[61]
Respiratory Failure	Other diseases of the respiratory system (J95-J99)	3.67	[61]
Interstitial Lung Disease	Other respiratory diseases principally affecting the interstitium (J80-J84)	7.00	[61]
Atopic Dermatitis	Dermatitis and eczema (L20-L30)	1.11	[61]
Urticaria	Urticaria and erythema (L50-L54)	1.40	[61]
Herpesviral vesicular dermatitis	Viral infections characterized by skin and mucous membrane lesions (B00-B09)	1.43	[61]
Sleep Apnea	Episodic and paroxysmal disorders (G40-G47)	1.75	[61]
Transient ischemic attacks	Episodic and paroxysmal disorders (G40-G47)	1.62	[62]
Hemorrhagic stroke	Cerebrovascular diseases (I60-I69)	2.19	[62]
Cerebral venous thrombosis	Cerebrovascular diseases (I60-I69)	2.69	[62]
Alzheimer	Other degenerative diseases of the nervous system (G30-G32)	2.03	[62]
Dysautonomic	Other disorders of the nervous system (G90-G99)	1.3	[62]
Bells palsy	Nerve, nerve root and plexus disorders (G50-G59)	1.48	[62]
Stress and adjustment disorder	Neurotic, stress-related and somatoform disorders (F40-F48)	1.39	[62]
Psychotic disorder	Schizophrenia, schizotypal and delusional disorders (F20-F29)	1.51	[62]
Joint pain	Arthropathies (M00-M25)	1.34	[62]
Myalgia	Soft tissue disorders (M60-M79)	1.83	[62]
Myopathy	Diseases of myoneural junction and muscle (G70-G73)	2.76	[62]
Guillan Barre Syndrome	Polyneuropathies and other disorders of the peripheral nervous system (G60-G64)	2.16	[62]
Transverse Myelitis	Demyelinating diseases of the central nervous system (G35-G37)	1.49	[62]
Cholangitis	Disorders of gallbladder, biliary tract and pancreas (K80-K87)	2.02	[66]
IBS	Other diseases of intestines (K55-K63)	1.54	[66]
Acute Gastritis	Diseases of oesophagus, stomach and duodenum (K20-K31)	1.47	[66]
Functional Dyspepsie	Diseases of oesophagus, stomach and duodenum (K20-K31)	1.36	[66]
Acute Pancreatitis	Diseases of oesophagus, stomach and duodenum (K20-K31)	1.46	[66]
GERD	Diseases of oesophagus, stomach and duodenum (K20-K31)	1.35	[66]
PUD	Diseases of oesophagus, stomach and duodenum (K20-K31)	1.62	[66]

Table S2. Hazard Ratios of diagnoses affected by Covid shock simulation.




Figure S5. Impact of the Covid Shock Scenarios on multimorbidity pattern occurrence. We show the 20 most common multimorbidity cluster transitioned to in 2030 in the Covid Shock Scenario 1 (pessimistic scenario) and compare the relative occurrence for the standard scenario and both Covid Shock scenarios.